M3 (TSE:2413) Change In Receivables

: 円5,389 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

M3's change in receivables for the quarter that ended in Dec. 2023 was 円-1,853 Mil. It means M3's Accounts Receivable increased by 円1,853 Mil from Sep. 2023 to Dec. 2023 .

M3's change in receivables for the fiscal year that ended in Mar. 2023 was 円3,085 Mil. It means M3's Accounts Receivable declined by 円3,085 Mil from Mar. 2022 to Mar. 2023 .

M3's Accounts Receivable for the quarter that ended in Dec. 2023 was 円54,061 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. M3's Days Sales Outstanding for the three months ended in Dec. 2023 was 77.82.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. M3's liquidation value for the three months ended in Dec. 2023 was 円97,463 Mil.

M3 Change In Receivables Historical Data

The historical data trend for M3's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

M3 Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

-2,736.00

-4,216.00

-9,488.00

-8,836.00

3,085.00

M3 Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-7,269.00	6,600.00	2,944.00	-2,302.00	-1,853.00

M3 Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5,389 Mil.

M3 (TSE:2413) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

M3's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	54061	/	63394	*	91
=	77.82

2. In Ben Graham's calculation of liquidation value, M3's accounts receivable are only considered to be worth 75% of book value:

M3's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	169629	-	112712	+	0.75 * 54061	+	0.5 * 0
=	97,463

M3 Change In Receivables Related Terms

Thank you for viewing the detailed overview of M3's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

M3 (TSE:2413) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » M3 Inc (TSE:2413) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MTHRY:USA MTHRF:USA 4YC:Germany

Address

Akasaka Intercity 10th floor, 1-11-44 Akasaka, Minato-ku, Tokyo, JPN, 105-0012

Website

http://corporate.m3.com

M3, Inc. is a Japan-based company engaged in providing medical-related services through the use of the Internet. It also supports marketing of pharmaceutical companies and medical equipment manufacturers. The company's business segment includes, Medical Portal segment, Evidence Solution segment, Overseas segment, Clinical Platform segment, Sales Platform segment, and Others. The company generates the majority of its revenue from Medical Portal segment.

M3 (TSE:2413) Headlines

No Headlines